Extensior South Africa Launch Targets Lower-Cost Access

Original Article by Nqobile Dludla | Reuters | 17 July 2026

The Extensior South Africa launch on 27 July, offering patients a lower-cost, authorised semaglutide treatment for type 2 diabetes.

Extensior South Africa Launch Targets Lower-Cost Access

Image | Peter Hansen | iStock/1743274641

Novo Nordisk is preparing to launch a lower-cost, authorised version of Ozempic in South Africa. The Extensior South Africa launch aims to improve access to regulated semaglutide treatment for people with type 2 diabetes.

Extensior is scheduled to become available from 27 July. Novo Nordisk has partnered with pharmaceutical company Acino to distribute the medicine nationwide.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

Ambulance Tariff Negotiations Seek Competition Exemption

Ambulance tariff negotiations could help private emergency service providers address low payments, cash-flow pressure and market contraction.

Discovery Health Membership Growth and Challenges Ahead

Learn how Discovery Health aims for robust membership growth amid challenges posed by churn and an aging member pool.

Medscheme Bonitas Court Bid Withdrawal Clears CMS Probe

Medscheme Bonitas Court Bid withdrawal allows the CMS to resume its forensic probe into disputed Bonitas procurement processes.

Extensior South Africa Launch Targets Lower-Cost Access

Subscription Required

More Posts

Ambulance Tariff Negotiations Seek Competition Exemption

Discovery Health Membership Growth and Challenges Ahead

Medscheme Bonitas Court Bid Withdrawal Clears CMS Probe